Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors
Modern Rheumatology,

Kita J et al. – Delayed treatment with tumor necrosis factor (TNF) inhibitors is effective and tolerable for patients with very early rheumatoid arthritis (RA) with poor prognosis factors.

Methods
  • The authors examined 22 patients with very early RA who were positive for anti–cyclic citrullinated peptide antibodies or IgM–rheumatoid factor.
  • The mean disease duration at entry was 14.1 weeks.
  • A treat–to–target strategy, aiming at simplified disease activity index (SDAI) remission, was initiated with synthetic DMARDs.

Results
  • SDAI remission was not achieved in 9 of the 22 patients with synthetic DMARDs alone, and TNF inhibitors were added in these patients.
  • SDAI values in these 9 patients were further examined for the following 6 months.
  • The TNF inhibitors (infliximab 8, etanercept 1) were added at a mean interval of 34.1 weeks after the initiation of synthetic DMARDs.
  • SDAI remission was achieved in 4 of the 9 patients (44.4%) at 3 months and in 8 of the 9 patients (88.9%) at 6 months after the introduction of the TNF inhibitors.
  • Radiographic damage had not progressed in these patients.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close